Pulmonary Metastatic Osteosarcoma

checkorphan

Synonyms

Osteosarcoma,

Overview

Pulmonary metastatic osteosarcoma means osteosarcoma, a bone cancer, has spread to the lungs, the most common site, occurring in ~20% of patients at diagnosis and more later, causing symptoms like cough/chest pain, appearing as lung nodules on CT scans, and managed with chemotherapy & often surgery (metastasectomy) for better survival, despite being a major cause of death in OS. 

Symptoms

Pulmonary metastatic osteosarcoma symptoms often involve respiratory issues like a persistent cough (sometimes with blood), shortness of breath, and chest pain, along with general cancer signs like unexplained weight loss and fatigue, though early lung spread can be silent. These symptoms arise as tumors grow in the lungs, potentially blocking airways, causing inflammation, or leading to complications like pneumothorax (collapsed lung). 

Causes

Pulmonary metastatic osteosarcoma happens when cancer cells from the original bone tumor break off and travel to the lungs, primarily through hematogenous spread (the bloodstream), with the lungs being the most common site for this spread, making it a frequent complication. The process involves cancer cells adapting to the lung environment, often making it seem like a “wounded” area that can’t heal, which promotes further tumor growth, driven by complex molecular interactions between the tumor and the lung’s immune cells. 

Prevention

Preventing pulmonary metastases (lung spread) from osteosarcoma focuses on early detection and aggressive treatment, using chemotherapy, surgery (like lung resection), radiation, and promising new immunotherapies (like OST-HER2), with ongoing research targeting anti-angiogenic therapies (endostatin) and cell stiffness to stop dormant cells from growing, though no lifestyle changes definitively prevent it. 

Diagnosis

Diagnosing pulmonary metastatic osteosarcoma (OS) primarily relies on Chest CT scans, the gold standard, revealing characteristic multiple, well-defined, rounded nodules (often calcified or with halos) in the lungs, sometimes atypical (cavitation, ground-glass appearance). Diagnosis confirms metastasis when nodules appear or grow after primary OS diagnosis, with imaging changes (nodule count/size) post-chemotherapy strongly supporting it, though biopsy might be needed for confirmation, especially for atypical presentations. 

Prognosis

The prognosis for pulmonary metastatic osteosarcoma is generally poor but variable, with 5-year survival rates often around 30%, significantly lower than non-metastatic cases (65-75%). Key factors influencing prognosis include successful complete surgical resection (metastasectomy), which significantly improves outcomes, the number and size of lung lesions (fewer and smaller is better), response to chemotherapy (better grade = better survival), and potentially the timing of metastasis. While surgery offers the best chance for long-term survival, recurrence, often in the lungs, is common, necessitating aggressive, often repeated, multimodal treatment.

Treatment

Treatment for pulmonary metastatic osteosarcoma typically involves a combination of aggressive multi-drug chemotherapy (like Methotrexate, Doxorubicin, Cisplatin) and surgery (pulmonary metastasectomy) to remove lung nodules, aiming for long-term survival or potential cure, often with surgical removal of the primary tumor too, managed by a multidisciplinary team. Newer approaches explore targeted therapies, radiosurgery (SRS), and other local treatments, but chemo-surgery remains the backbone.